Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
188 hedge funds and large institutions have $1.22B invested in Avadel Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 58 increasing their positions, 61 reducing their positions, and 18 closing their positions.
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
69% more capital invested
Capital invested by funds: $721M → $1.22B (+$500M)
65% more call options, than puts
Call options by funds: $31M | Put options by funds: $18.9M
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
9% more funds holding
Funds holding: 173 → 188 (+15)
5% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 61
1.84% less ownership
Funds ownership: 84.2% → 82.36% (-1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$15.5M |
| 2 |
Morgan Stanley
New York
|
+$13.9M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$8.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$6.84M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$48.2M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$13.6M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
-$10.2M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$7.11M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.12M |
AVDL Hedge Fund Activity: Q3 2025 in Review
188 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2025, worth a combined $1.22B — up 69% from $721M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AVDL positions and 18 closed out — a net gain of 18 holders — while 58 added to existing stakes and 61 trimmed.
The largest buyer was Bank of America, adding an estimated $15.5M. The largest seller was Janus Henderson Group, cutting an estimated $48.2M.
- 188 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2025, up from 173 in Q2 2025.
- Funds reported $1.22B of Avadel Pharmaceuticals stock for Q3 2025, up 69% quarter-over-quarter.
- 36 funds opened new Avadel Pharmaceuticals positions in Q3 2025 and 18 closed out, a net change of +18 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2025 was Bank of America, an estimated $15.5M added.
- The largest Avadel Pharmaceuticals seller in Q3 2025 was Janus Henderson Group, an estimated $48.2M sold.
Based on aggregated 13F filings for Q3 2025.